News – Page 1065 – Endpoints News

A transpacific biotech startup combines Asian investors and some seriously trendy science out of MIT

8 years ago

Brain damage cases force an FDA hold on Bellicum's lead cell therapy -- shares tank

8 years ago

Counting its remaining cash, Vical axes 40 staffers and circles wagons around two Phase II assets

8 years ago

Eyeing a multibillion-dollar market, Shire snags preclinical IVIg rival from AB Biosciences

8 years ago

Sunovion scores on PhIII Parkinson's study, shooting for showdown with Acorda; Puma out-licenses neratinib to Israeli ...

8 years ago

Gene therapy pioneer James Wilson sounds an alarm on high-dose AAV studies following toxic reactions in monkeys

8 years ago

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

8 years ago

Merck R&D chief Roger Perlmutter offers some heavyweight R&D glam to a little upstart biotech out to cure Duchenne MD

8 years ago

Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics

8 years ago

Corbus Pharma reels in $25M to pay for its PhIIb cystic fibrosis study, shares sink

8 years ago

After a legendary stint at Celgene's helm, biopharma vet Bob Hugin is on his way out — as Senate race rumors swirl

8 years ago

Roche touts CHMP nod for Hemlibra; Alder raises $200M for migraine drug launch

8 years ago

Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D

8 years ago

Suspicious returns trigger insider trading suit following $11.6B Bioverativ deal

8 years ago

Roche scores an unusual ‘breakthrough’ at the FDA for an autism drug

8 years ago

Aradigm completes disastrous regulatory run as FDA slaps down Linhaliq application

8 years ago

Sorry Novo: Sanofi wins Ablynx over with $4.8B buyout bid, bagging nanobody platform tech

8 years ago

In post-IPO party, Nasdaq’s newcomers Armo, Menlo and Solid soar within hours of listing

8 years ago

Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout

8 years ago

Vas Narasimhan joins the power circle at Davos; Armo Bio, resTORbio raises $128M and $85M in IPO

8 years ago

Heptares co-founder Fiona Marshall to lead Merck's London research hub; Ablynx appoints Robert Friesen as new CFO

8 years ago

Ex-Merrimack CEO Mulroy launches oncology startup Partner Therapeutics

8 years ago

When will Biogen finally pull the trigger on a blockbuster M&A deal?

8 years ago

Behind the deal spree, Celgene continues to cautiously explore neurosciences

8 years ago

First page Previous page 1062 1063 106410651066 1067 1068 Next page Last page